Suggested Dosing
Exercise Performance Enhancement
Load: 20 g PO qDay x 5 days
Maint: 2-3 g PO qDay
CHF
20 g PO daily x 5-10 day
Parkinson's Disease
10 g PO qDay
Gyrate Atrophy
1.5 g PO daily
McArdle Disease
Initial: 150 mg/kg/day x 5 day, THEN
60 mg/kg/day PO
Muscular Dystophies
10 g PO daily
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)
10 g PO qDay x 12-16 months
Idiopathic Inflammatory Myopathies
20 g/day x 8 days, THEN
3 g/day x 6 months
Amyotrophic Lateral Sclerosis (Orphan)
Orphan indication sponsor
- Avicena Group, Inc; 228 Hamilton Avenue; Palo Alto, CA 94301
Huntington's Disease (Orphan)
Indicated for treatment of mitochondrial cytopathies
Orphan indication sponsor
- Avicena Group, Inc; 228 Hamilton Avenue; Palo Alto, CA 94301
Suggested Uses
Amyotrophic lateral sclerosis, CHF, exercise performance enhancement, gyrate atrophy, McArdle disease, mitochondrial cytopathies, muscle mass builder, muscular dystrophies, neuromuscular disease, rheumatoid arthritis, Parkinson's disease,
Efficacy
Athletic performance: seems to enhance muscle performance during repeated bouts of brief, high-intensity exercise. Does not seem to improve performance in aerobic exercises, or benefit older individuals OR highly trained athletes
CHF: When taken orally improves exercise tolerance but does not affect the ejection fraction. IV creatinine improves cardiac function, including ejection fraction
Gyrate atrophy: seems to slow visual deterioration
McArdle's disease: Preliminary clinical evidence that it can increase exercise capacity & decrease exercise-induced muscle pain
Parkison's disease: Some evidence shows that it can decrease rate of disease progression in early stages
Idiopathic inflammatory myopathies: more evidence is needed to determine effectiveness
Possibly ineffective for amyotrophic lateral sclerosis, rheumatoid arthritis, & schizophrenia
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (46)
- aceclofenac
creatine, aceclofenac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- acemetacin
creatine, acemetacin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- aspirin
creatine, aspirin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- aspirin rectal
creatine, aspirin rectal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- aspirin/citric acid/sodium bicarbonate
creatine, aspirin/citric acid/sodium bicarbonate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- benazepril
creatine, benazepril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- celecoxib
creatine, celecoxib. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- choline magnesium trisalicylate
creatine, choline magnesium trisalicylate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- cyclosporine
creatine, cyclosporine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- diclofenac
creatine, diclofenac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- diflunisal
creatine, diflunisal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- enalapril
creatine, enalapril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- entecavir
creatine, entecavir. Either increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.
- etodolac
creatine, etodolac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- fenbufen
creatine, fenbufen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- fenoprofen
creatine, fenoprofen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- flurbiprofen
creatine, flurbiprofen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- fosinopril
creatine, fosinopril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- ibuprofen
creatine, ibuprofen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- ibuprofen IV
creatine, ibuprofen IV. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- imidapril
creatine, imidapril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- indomethacin
creatine, indomethacin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- ketoprofen
creatine, ketoprofen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- ketorolac
creatine, ketorolac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- ketorolac intranasal
creatine, ketorolac intranasal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- lisinopril
creatine, lisinopril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- lornoxicam
creatine, lornoxicam. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- meclofenamate
creatine, meclofenamate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- mefenamic acid
creatine, mefenamic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- meloxicam
creatine, meloxicam. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- moexipril
creatine, moexipril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- nabumetone
creatine, nabumetone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- naproxen
creatine, naproxen. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- oxaprozin
creatine, oxaprozin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- parecoxib
creatine, parecoxib. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- perindopril
creatine, perindopril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- piroxicam
creatine, piroxicam. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- quinapril
creatine, quinapril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- ramipril
creatine, ramipril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- salicylates (non-asa)
creatine, salicylates (non-asa). Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- salsalate
creatine, salsalate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- sulfasalazine
creatine, sulfasalazine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- sulindac
creatine, sulindac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- tolfenamic acid
creatine, tolfenamic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- tolmetin
creatine, tolmetin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
- trandolapril
creatine, trandolapril. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.
Adverse Effects
Abdominal pain, arrhythmias, cardiac arrest, cardiomyopathy, dehydration, diarrhea, hypertension, ischemic stroke, muscle cramping, nausea, renal dysfunction, rhabdomyolysis, seizures, weight gain
Warnings
Contraindications
Diabetes mellitus, nephrotic syndrome
Cautions
Concurrent nephrotoxic agents
Pregnancy & Lactation
Pregnancy Category: avoid use
Lactation: avoid use
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Metabolism: N/A
Excretion: N/A
Mechanism of Action
Phosphocreatine serves as phosphate donor to generate ATP from ADP
